Testing Strategies throughout the Myeloma Disease Lifecycle
Release Date: April 26, 2017
Expiration Date: April 26, 2018
Expected time to complete this activity as designed: 30 minutes
There are no fees for participating in or receiving credit for this online activity.
The diagnosis, prognostication, and assessment of patients with myeloma spans a gamut of testing strategies, including identification of key abnormal laboratory values, cytogenetic aberrations, and evidence of radiographic disease. In addition to new IMWG diagnosis criteria and the Revised ISS, various clinical strategies have been developed to identify high-risk patients and guide treatment decisions. In this activity, Dr. McCarthy will discuss presenting symptomatology and diagnostic recommendations for patients suspected of having multiple myeloma, including prognostic tests that should be considered as part of the initial workup. The activity will conclude with a discussion of patients who relapsed from complete remission, as well as those who developed frank disease progression.
This activity is designed for physicians, pharmacists, physician assistants, and other health care professionals who have an interest in enhancing their clinical skills in multiple myeloma.
Upon completion of this educational activity, participants should be able to:
- Recognize patients suspected of having multiple myeloma and outline initial diagnostic and prognostic strategies
- Summarize testing strategies that should be implemented in patients with multiple myeloma who relapse
Testing Strategies throughout the Myeloma Disease Lifecycle – Philip L. McCarthy, MD
Instructions for Participation and Credit
This activity is eligible for credit through April 26, 2018. After this date, this activity will expire and no further credit will be awarded.
- Read the target audience, learning objectives, and faculty disclosures.
- You may be asked to complete a short pre-test before accessing the educational content. This must be completed in order to move forward in the activity.
- Complete the educational content as designed.
- Complete the post-test. To receive a certificate, you must receive a passing score of 70%.
- Complete the activity evaluation survey to provide feedback and information useful for future programming.
- Certificates for CME credit may be printed immediately after successfully completing the post-test and activity evaluation. Pharmacist credit will be uploaded to CPE Monitor 4 weeks following receipt of a completed, qualified form.
Philip L. McCarthy, MD
Professor of Oncology
Director, Blood and Marrow Transplant Program
Roswell Park Cancer Institute
Buffalo, New York
Dr. Philip McCarthy received his medical degree from Tufts University School of Medicine, Boston, Massachusetts. He completed an internship and residency at Yale-New Haven Hospital, and hematology and medical oncology fellowship training at Brigham and Women's Hospital and Dana Farber Cancer Institute. Dr. McCarthy is Professor of Oncology and Director of the Blood and Marrow Transplant Program at Roswell Park Cancer Institute, Buffalo. He is also Professor of Internal Medicine at the State University of New York at Buffalo.
Dr. McCarthy is a diplomate, American Board of Internal Medicine, with subspecialty certification in medical oncology and hematology, and holds membership in the American Society of Hematology (ASH), American Society for Blood and Marrow Transplantation (ASBMT), American Society of Clinical Oncology (ASCO), American Association of Blood Banking (AABB), and the American Association for Cancer Research (AACR). He is associate chair of the Myeloma Committee of the Alliance for Clinical Trials in Oncology (ACTION) and a member of the Transplant Committee. He is an associate editor of the Biology of Blood and Marrow Transplantation journal, as well as an ad hoc reviewer for several journals including Blood, Bone Marrow Transplantation, Journal of Clinical Oncology, Haematologica, Leukemia and Lymphoma, and JNCCN. Dr. McCarthy has published more than 200 peer-reviewed manuscripts and reviews. His major research interests include blood and marrow transplantation, graft-versus-host disease/graft-versus-tumor effect, cancer immunotherapy, and multiple myeloma.
Accreditation Statement: MediCom Worldwide, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation Statement: MediCom Worldwide, Inc. designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MediCom Worldwide, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This activity is acceptable for 0.5 contact hours of Continuing Education Credit. Universal Activity Number: 827-0000-17-143-H01-P. Knowledge-based CPE activity.
In order for CPE Monitor to authenticate credit, pharmacists/technicians must provide their e-Profile ID number from NABP and date of birth (in MMDD format) when claiming credit for a CPE program.
As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE) and California State Board of Registered Nursing, MediCom Worldwide, Inc. requires everyone who is in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest. Accordingly, the following disclosures were made.
Dr. Philip McCarthy has received honoraria as a consultant from Bristol-Myers Squibb Company, Celgene Corporation, Karyopharm Therapeutics, and Sanofi. He has received grant support related to research activities from Celgene.
Planning Committee Disclosures
The individuals listed below from MediCom Worldwide, Inc. reported the following for this activity: Joan Meyer, RN, MHA, Executive Director, has no relevant financial relationships.
Peer Reviewer Disclosure
In accordance with MediCom Worldwide, Inc. policy, all content is reviewed by external independent peer reviewers for balance, objectivity and commercial bias. The peer reviewers have no relevant financial relationships to disclose.
If you have any questions or concerns regarding this activity, please contact MediCom Worldwide, Inc. at 1-800-408-4242 or email us at firstname.lastname@example.org
Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Celgene Corporation and Takeda Oncology.
©2017 MediCom Worldwide, Inc., 101 Washington St., Morrisville, PA 19067, 800-408-4242.
No portion of this material may be copied or duplicated without the expressed permission of MediCom Worldwide, Inc.